Rachel S Kerr et al.
The Lancet. Oncology, 17(11), 1543-1557 (2016-09-24)
Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. For the open-label, randomised, controlled QUASAR 2 trial, which was